The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma

Abstract The management of metaplastic breast carcinoma (MBC) has largely paralleled the paradigms used for invasive ductal carcinoma (IDC) in the current National Comprehensive Cancer Network guidelines of breast cancer. However, patients with IDC and MBC have been shown to have a different prognos...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	San-Gang Wu, Shi-Ping Yang, Wen-Wen Zhang, Jun Wang, Chen-Lu Lian, Yong-Xiong Chen, Zhen-Yu He
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9d01d86d50564ea6b958c0cc58461fcf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9d01d86d50564ea6b958c0cc58461fcf
record_format	dspace
spelling	oai:doaj.org-article:9d01d86d50564ea6b958c0cc58461fcf2021-12-02T13:58:13ZThe longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma10.1038/s41598-020-79166-52045-2322https://doaj.org/article/9d01d86d50564ea6b958c0cc58461fcf2020-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-79166-5https://doaj.org/toc/2045-2322Abstract The management of metaplastic breast carcinoma (MBC) has largely paralleled the paradigms used for invasive ductal carcinoma (IDC) in the current National Comprehensive Cancer Network guidelines of breast cancer. However, patients with IDC and MBC have been shown to have a different prognosis, and there are significant differences in risk and failure patterns after treatment. The purpose of this study was to compare breast cancer specific survival (BCSS) and hazard function between IDC and MBC. We included patients from the Surveillance, Epidemiology, and End Results program with stage I-III IDC and MBC between 2000 and 2012. Statistical analyses were including chi-square analysis, life-table methods, multivariate Cox proportional hazards models, and propensity score matching (PSM). We identified 294,719 patients; 293,199 patients with IDC and 1520 patients with MBC. Multivariate analyses showed that the MBC subtype had significantly lower BCSS than the IDC subtype before and after PSM (p < 0.001). There were significant differences in the hazard curve between IDC and MBC. The hazard curve for breast cancer mortality in the IDC cohort peaked at 3 years (2%), and then changed to a slowly decreasing plateau after prolonged follow up. However, the hazard curve for breast cancer mortality in the MBC cohort peaked at 2 years (7%), then declined sharply between 3 and 6 years, and changed to a low death rate after a follow-up time exceeding 6 years. Subgroup analyses revealed that the hazard curves significantly differed between IDC and MBC after stratifying by tumor stage and hormone receptor status. Our study suggests that patients with MBC should receive more effective systemic agents and intensive follow-up because of their significantly augmented risk of death compared to IDC patients.San-Gang WuShi-Ping YangWen-Wen ZhangJun WangChen-Lu LianYong-Xiong ChenZhen-Yu HeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q San-Gang Wu Shi-Ping Yang Wen-Wen Zhang Jun Wang Chen-Lu Lian Yong-Xiong Chen Zhen-Yu He The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma
description	Abstract The management of metaplastic breast carcinoma (MBC) has largely paralleled the paradigms used for invasive ductal carcinoma (IDC) in the current National Comprehensive Cancer Network guidelines of breast cancer. However, patients with IDC and MBC have been shown to have a different prognosis, and there are significant differences in risk and failure patterns after treatment. The purpose of this study was to compare breast cancer specific survival (BCSS) and hazard function between IDC and MBC. We included patients from the Surveillance, Epidemiology, and End Results program with stage I-III IDC and MBC between 2000 and 2012. Statistical analyses were including chi-square analysis, life-table methods, multivariate Cox proportional hazards models, and propensity score matching (PSM). We identified 294,719 patients; 293,199 patients with IDC and 1520 patients with MBC. Multivariate analyses showed that the MBC subtype had significantly lower BCSS than the IDC subtype before and after PSM (p < 0.001). There were significant differences in the hazard curve between IDC and MBC. The hazard curve for breast cancer mortality in the IDC cohort peaked at 3 years (2%), and then changed to a slowly decreasing plateau after prolonged follow up. However, the hazard curve for breast cancer mortality in the MBC cohort peaked at 2 years (7%), then declined sharply between 3 and 6 years, and changed to a low death rate after a follow-up time exceeding 6 years. Subgroup analyses revealed that the hazard curves significantly differed between IDC and MBC after stratifying by tumor stage and hormone receptor status. Our study suggests that patients with MBC should receive more effective systemic agents and intensive follow-up because of their significantly augmented risk of death compared to IDC patients.
format	article
author	San-Gang Wu Shi-Ping Yang Wen-Wen Zhang Jun Wang Chen-Lu Lian Yong-Xiong Chen Zhen-Yu He
author_facet	San-Gang Wu Shi-Ping Yang Wen-Wen Zhang Jun Wang Chen-Lu Lian Yong-Xiong Chen Zhen-Yu He
author_sort	San-Gang Wu
title	The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma
title_short	The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma
title_full	The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma
title_fullStr	The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma
title_full_unstemmed	The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma
title_sort	longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/9d01d86d50564ea6b958c0cc58461fcf
work_keys_str_mv	AT sangangwu thelongitudinalriskofmortalitybetweeninvasiveductalcarcinomaandmetaplasticbreastcarcinoma AT shipingyang thelongitudinalriskofmortalitybetweeninvasiveductalcarcinomaandmetaplasticbreastcarcinoma AT wenwenzhang thelongitudinalriskofmortalitybetweeninvasiveductalcarcinomaandmetaplasticbreastcarcinoma AT junwang thelongitudinalriskofmortalitybetweeninvasiveductalcarcinomaandmetaplasticbreastcarcinoma AT chenlulian thelongitudinalriskofmortalitybetweeninvasiveductalcarcinomaandmetaplasticbreastcarcinoma AT yongxiongchen thelongitudinalriskofmortalitybetweeninvasiveductalcarcinomaandmetaplasticbreastcarcinoma AT zhenyuhe thelongitudinalriskofmortalitybetweeninvasiveductalcarcinomaandmetaplasticbreastcarcinoma AT sangangwu longitudinalriskofmortalitybetweeninvasiveductalcarcinomaandmetaplasticbreastcarcinoma AT shipingyang longitudinalriskofmortalitybetweeninvasiveductalcarcinomaandmetaplasticbreastcarcinoma AT wenwenzhang longitudinalriskofmortalitybetweeninvasiveductalcarcinomaandmetaplasticbreastcarcinoma AT junwang longitudinalriskofmortalitybetweeninvasiveductalcarcinomaandmetaplasticbreastcarcinoma AT chenlulian longitudinalriskofmortalitybetweeninvasiveductalcarcinomaandmetaplasticbreastcarcinoma AT yongxiongchen longitudinalriskofmortalitybetweeninvasiveductalcarcinomaandmetaplasticbreastcarcinoma AT zhenyuhe longitudinalriskofmortalitybetweeninvasiveductalcarcinomaandmetaplasticbreastcarcinoma
_version_	1718392216727060480

The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma

Ejemplares similares